Global Point of Care
At-home, virtually guided COVID-19 antigen testing provides rapid and verifiable results in the safety and convenience of your home.
The 15-minute BinaxNOW™ COVID-19 Ag Card Home Test has received FDA Emergency Use Authorization for at-home testing in collaboration with eMed, a digital health solution. This first-of-its kind service for COVID-19 testing ships tests directly to your home and uses trained, virtual proctors to guide you through the test via video call. The complementary NAVICA™ mobile app to enables the testing process and displays BinaxNOW COVID-19 test results that are shareable at workplaces, organizations, or events that require proof of test for entry.
Prescription home use. Only available in the US.
When you download the NAVICA mobile app to your smartphone or tablet, you will be able to:
Our rapid COVID-19 tests and NAVICA system work together as a comprehensive solution to easily view, share, confirm and manage COVID-19 test results.
Download NAVICA, the first-of-its-kind app, from both the App Store® and Google Play™ store.
The BinaxNOW COVID-19 Ag Card Home Test, the NAVICA app, and eMed digital health solution provide peace of mind with reliable, rapid testing in the safety and convenience of home.
In addition to the BinaxNOW COVID-19 Ag Home Test, Abbott offers a BinaxNOW COVID-19 Antigen Card Self Test, which is available over-the-counter and does not require a prescription. Abbott also offers the BinaxNOW COVID-19 Ag Card test to organizations such as schools, employers and healthcare professionals for their own testing programs.
The BinaxNOW™ COVID-19 Ag Card Home test is available via the NAVICA App. Visit the App Store or Google Play to download and view the “Home Test” tab for information specific to your location.
Please visit eMed.com or contact eMed Customer Support for more information: (844)-943-0753.
Google Play and the Google Play Logo are trademarks of Google LLC.
App Store and the Apple Logo are trademarks of Apple Inc.
The BinaxNOW™ COVID-19 Ag Card Home Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
a leader in rapid point-of-care diagnostics.
©2023 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement | Declaration for California Compliance Law.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.